Does oral vancomycin use necessitate therapeutic drug monitoring?

Cimolai, Nevio

doi:10.1007/s15010-019-01374-7

Cited by 13 publications

(7 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The standard dose of 125 mg four times daily already results in high intraluminal levels [182], and high dose vancomycin increases risk of possible adverse effects, e.g. systemic levels of vancomycin [183]. Additonally, concerns regarding increased antibiotic selection pressure resulting in resistance selection (e.g.…”

Section: High Dose Vancomycinmentioning

confidence: 99%

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

Prehn

Reigadas

Vogelzang

et al. 2021

Clinical Microbiology and Infection

360

320

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: High Dose Vancomycinmentioning

confidence: 99%

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

Prehn

Reigadas

Vogelzang

et al. 2021

Clinical Microbiology and Infection

360

320

View full text Add to dashboard Cite

show abstract

“…Although vancomycin has been FDA approved and used to treat MRSA-and C. difficile-colitis, it has been found to induce peripheral rash, anaphylaxis, "red man syndrome", ototoxicity and nephrotoxicity [171,172]. Daptomycin is used as an alternative to vancomycin and FDA approved for MRSA bloodstream infections.…”

Section: Discussion and Further Insightsmentioning

confidence: 99%

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Patrulea¹,

Borchard²,

Jordan³

2020

Preprint

View full text Add to dashboard Cite

Bacterial infections occur when wound healing fails to reach the final stage of healing, usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site accompanied very often by an increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies, such as polymers, scaffolds, films and wound dressings, organic and inorganic nanoparticles, to combat infection and modulate the healing rate have been discussed as well. New technologies such as CRISPR-Cas are taken into consideration as potential future tools for AMP delivery in skin therapy.

show abstract

“…Although vancomycin was generally considered to be nonabsorbable through gastral administration, 17 there were a few case reports of 'red man syndrome' , 18,19 ototoxicity or encephalopathy related to oral vancomycin. 19,20 In this work, we detected a distinct and stable serum concentration for 20 days in one patient during nasal vancomycin administration alone after stopping intravenous usage. This indicated that gastral vancomycin might be absorbed.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Vancomycin in Severe COVID-19 Patients: a Preliminary Study in a Chinese Tertiary Hospital

Yin¹,

Qi²,

Chen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Vancomycin plays an important role in the treatment of concurrent infections in severe coronavirus disease 2019 (COVID-19) patients. However, few is known about its pharmacokinetics (PK) in these patients. Here we performed therapeutic drug monitoring (TDM) of intravenous vancomycin with or without nasal administration in these patients. Drug dosage was adjusted depending on vancomycin concentration. A population PK model was developed using NONMEM software. Therapeutic effects, and vancomycin-related adverse events were monitored. A total of 63 samples from 8 patients were analyzed by ultra-performance liquid chromatography-tandem mass spectrometry. The mean trough and peak concentration were 13.79±6.61 (4.63-34.2) mg/L (n=36) and 30.97±9.71 (17-49.9) mg/L (n=27), respectively. 25.4% of serum vancomycin concentration was beyond optimal range. Dose adjustments were made for 3 patients. The PK of vancomycin was consistent with two-compartment model, with the clearance and distribution volume in the central compartment of 4.3 L/h and 2.0 L, respectively. The AUC0-24/MIC of vancomycin was 848±566 h. Target infection was clinically cured in all patients, and no vancomycin-associated nephrotoxicity was detected during the TDM process. In conclusion, the PK studies of vancomycin in COVID-19 patients are needed to optimize drug dosage. Based on our PK model, the clearance of vancomycin was 4.3 L/h.

show abstract

Does oral vancomycin use necessitate therapeutic drug monitoring?

Cited by 13 publications

References 80 publications

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Pharmacokinetics and Pharmacodynamics of Vancomycin in Severe COVID-19 Patients: a Preliminary Study in a Chinese Tertiary Hospital

Contact Info

Product

Resources

About